…for patient comfort.
Q1 FYE3/2026 Results
Date of Release: July 31, 2025 Earnings Call: Same as above
Japan Lifeline Co., Ltd.TSE Prime Market Ticker 7575
Unauthorized copying prohibited.
Copyright © 2025 Japan Lifeline Co., Ltd. All rights reserved.
Q1 FYE3/2026 Results
Q&A Session
Appendix 1 Reference Materials Appendix 2 Investors Guide (Summary)
A fact sheet is available in PDF or excel on our website at https://www.japanlifeline.com/investors/ 2
Q1 FYE3/2026 Results
Q&A Session
Appendix 1 Reference Materials Appendix 2 Investors Guide (Summary)
A fact sheet is available in PDF or excel on our website at https://www.japanlifeline.com/investors/ 3
Highlights
(¥mn) | Q1 FYE3/2026 |
Net Sales | 14,616 + 4.3% YoY |
Operating Profit | 3,272 + 2.4% YoY |
Net Profit | 2,302 (1.6%) YoY |
External
Factors
(+) AF procedures +5-6% YoY
--> Excl. conference impact: +8-9% growth*¹ (ー) PFA impacts on select products
(ー) Official price revisions (2-month impact)*²
Internal Factors
(+) Strong core products*3 performance
(+) New therapeutic areas +47% YoY
(ー) R&D and SG&A expense increases
*1 Impact of a major arrhythmia-related conference organized by Japan Heart Rhythm Society held in May 2025. In the previous period, this conference was held in November 2024 (Q3). Since physicians from across the country join this conference, the number of cases decreases before and after the event. *2 Official prices were revised in June 2024. Sales prices in April and May declined 4 compared to the same months in the previous year *3 The core products: (1) Intracardiac defibrillation catheter (BeeAT), (2) Femoral vein hemostatic device, (3) S-ICD, and (4) Frozen Elephant Trunk
Revenue growth, operating profit up. Net profit down
(¥mn except for per share amount) | Q1 FYE3/2025 | Q1 FYE3/2026 | Change | Change% | Comments |
Net sales | 14,010 | 14,616 | + 605 | + 4.3 | (+) Sales volume increased with more cases (+) New therapeutic areas expanded |
Gross profit | 8,583 | 8,769 | + 186 | + 2.2 | (ー) Reimbursement revision implemented (impact: 2-months) (ー) Proprietary sales mix decreased |
％ | 61.3% | 60.0% | (130bps) | ||
SG&A | 5,388 | 5,497 | + 108 | + 2.0 | See next page |
Operating profit | 3,194 | 3,272 | + 77 | + 2.4 | See next page |
％ | 22.8% | 22.4% | (40bps) | ||
Net profit | 2,340 | 2,302 | (37) | (1.6) | (ー) Higher FX losses (ー) Increased asset disposal losses |
％ | 16.7% | 15.8% | (90bps) | ||
Proprietary sales mix | 58.2% | 55.6% | (260bps) | Procured products expansion: neuro & hemostatic devices; Proprietary products decline including esophageal catheters*1 | |
International sales mix | 2.0% | 2.4% | + 40 bps | ||
EPS (¥) | 31.95 | 32.85 | + 0.90 | + 2.8 | (+) Outstanding shares (average for period) decreased |
*1 Proprietary product sales decreased 0.5% YoY, while procured product sales increased 10.8% YoY
| Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |